Curetis starts prospective clinical trial for Unyvero P50 pneumonia application

Curetis AG today announced the start of an additional prospective, multicenter clinical trial of its marketed Unyvero™ P50 Pneumonia Application to demonstrate its clinical and health economic value.

The CE performance evaluation completed last year already demonstrated 81% sensitivity at 99% specificity for detecting pneumonia-causing pathogens. Following the market launch in April 2012, Curetis in 2013 presented data from more than 1,000 patient samples showing overall sensitivity of its pathogen panel of 80.6% at a specificity of 96% (ECCMID European Conference of Clinical Microbiology and Infectious Diseases, Berlin).

The new multicenter study aims to establish real-world data on the health economic impact of fast, patient-near molecular testing and subsequent therapy adjustments (if necessary). It will be conducted in five leading European centers and will involve several hundred critically ill patients with pneumonia requiring mechanical ventilation. The study is designed to first evaluate the current pneumonia treatment and clinical outcome situation  by detailed chart reviews comparing patients having received initial adequate, respectively inadequate treatment. Data will be used to fine tune endpoints for the interventional, randomized second part of the study, which aims to investigate the potential clinical and economic benefit of the Unyvero™ system. Parameters analyzed will be, e.g. type of antibiotic regimen and costs, length of stay in the ICU, etc.

Participating clinicians are world-renowned intensive care, pulmonology and microbiology specialists: Prof. Manfred Quintel (University of Goettingen), Prof. Tobias Welte (MHH University Clinic Hanover), Prof.s Philippe Eggimann and Gilbert Greub (CHUV University Hospital of Lausanne), Prof. Mathias Pletz (Jena University) and Prof. Antoni Torres (University Hospital Clinic Barcelona).

"A substantial number of medical studies demonstrate that initial inadequate empirical antibiotics treatment in pneumonia prolongs hospital stays, adds more than €5,000 in costs per patient and greatly increases mortality,” said Oliver Schacht, CEO of Curetis. “This suggests that early diagnosis can be very beneficial for patients and clinics. However, we are well aware that in today’s cost-sensitive healthcare systems the benefit of an innovative, fast diagnostic system needs to be proven in controlled studies. We are therefore very pleased to have won internationally renowned centers to participate in this study.”

"The Unyvero system is a breakthrough in the very fast, easy and reliable diagnosis of pneumonia," said Prof. Tobias Welte. “We are therefore very much looking forward to the study and the data it will generate.”

Source: http://www.curetis.com/